< sup > 225 < /sup > Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings
CONCLUSIONS: Given these favorable results, randomized prospective multicenter trials assessing the clinical value of 225Ac-PSMA-617 as a therapeutic agent for mHSPC administered either as monotherapy or administered concomitant with ADT are of interest.PMID:36864360 | DOI:10.1007/s00259-023-06165-9 (Source: Molecular Medicine)
Source: Molecular Medicine - March 2, 2023 Category: Molecular Biology Authors: Mike Sathekge Frank Bruchertseifer Mariza Vorster Ismaheel O Lawal Kgomotso Mokoala Janet Reed Letjie Maseremule Honest Ndlovu Khanyi Hlongwa Alex Maes Alfred Morgenstern Christophe Van de Wiele Source Type: research
Rucaparib or Physician's Choice in Metastatic Prostate Cancer
CONCLUSIONS: The duration of imaging-based progression-free survival was significantly longer with rucaparib than with a control medication among patients who had metastatic, castration-resistant prostate cancer with a BRCA alteration. (Funded by Clovis Oncology; TRITON3 ClinicalTrials.gov number, NCT02975934.).PMID:36795891 | DOI:10.1056/NEJMoa2214676 (Source: Cancer Control)
Source: Cancer Control - February 16, 2023 Category: Cancer & Oncology Authors: Karim Fizazi Josep M Piulats M Neil Reaume Peter Ostler Ray McDermott Joel R Gingerich Elias Pintus Srikala S Sridhar Richard M Bambury Urban Emmenegger Henriette Lindberg David Morris Franco Nol è John Staffurth Charles Redfern Mar ía I Sáez Wassim Ab Source Type: research
Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration ‐resistant prostate cancer
ConclusionsHigh SMI and low PPFA/PA could predict biochemical response to AA treatment and preferable prognosis in mCRPC patients with prior chemohormonal therapy at hormone-sensitive stage. (Source: Cancer Medicine)
Source: Cancer Medicine - February 8, 2023 Category: Cancer & Oncology Authors: Zhi ‐Bin Ke,
Qi You,
Yu‐Ting Xue,
Jiang‐Bo Sun,
Jia‐Yin Chen,
Wen‐Qi Liu,
Yong Wei,
Qing‐Shui Zheng,
Xiao‐Dong Li,
Xue‐Yi Xue,
Ning Xu Tags: RESEARCH ARTICLE Source Type: research
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer
Metastatic castration-resistant prostate cancer remains a challenging condition to treat. Among the available therapeutic options, the androgen receptor signaling inhibitors abiraterone acetate plus prednisone... (Source: Journal of Translational Medicine)
Source: Journal of Translational Medicine - February 3, 2023 Category: Research Authors: Pier Vitale Nuzzo, Filippo Pederzoli, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Valenca Bueno, Livia Maria Q. S. Andrade, Anna Patrikidou, Ricardo Pereira Mestre, Mikol Modesti, Sandro Pignata, Giuseppe Procop Tags: Research Source Type: research
The safety of radium-223 combined with new-generation hormonal agents in bone metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Asian J Androl. 2023 Jan 20. doi: 10.4103/aja2022108. Online ahead of print.ABSTRACTPatients with bone metastatic castration-resistant prostate cancer (mCRPC) might benefit from radium-223 (223Ra) combined with new-generation hormonal agents (NHAs) in terms of survival and quality of life (QoL). However, the safety of combination therapies remains unclear. Therefore, we aimed to perform a network meta-analysis by reviewing the literature about the combination of 223Ra with abiraterone acetate plus prednisone (AAP) or enzalutamide and to evaluate the safety of combination therapy in bone mCRPC patients. Ultimately, ten stud...
Source: Asian Journal of Andrology - January 25, 2023 Category: Urology & Nephrology Authors: Ming-Hao Wang Jin-Dong Dai Xing-Ming Zhang Jin-Ge Zhao Guang-Xi Sun Yu-Hao Zeng Hong Zeng Nan-Wei Xu Hao Zeng Peng-Fei Shen Source Type: research
The safety of radium-223 combined with new-generation hormonal agents in bone metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Asian J Androl. 2023 Jan 20. doi: 10.4103/aja2022108. Online ahead of print.ABSTRACTPatients with bone metastatic castration-resistant prostate cancer (mCRPC) might benefit from radium-223 (223Ra) combined with new-generation hormonal agents (NHAs) in terms of survival and quality of life (QoL). However, the safety of combination therapies remains unclear. Therefore, we aimed to perform a network meta-analysis by reviewing the literature about the combination of 223Ra with abiraterone acetate plus prednisone (AAP) or enzalutamide and to evaluate the safety of combination therapy in bone mCRPC patients. Ultimately, ten stud...
Source: Asian Journal of Andrology - January 25, 2023 Category: Urology & Nephrology Authors: Ming-Hao Wang Jin-Dong Dai Xing-Ming Zhang Jin-Ge Zhao Guang-Xi Sun Yu-Hao Zeng Hong Zeng Nan-Wei Xu Hao Zeng Peng-Fei Shen Source Type: research
The safety of radium-223 combined with new-generation hormonal agents in bone metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Asian J Androl. 2023 Jan 20. doi: 10.4103/aja2022108. Online ahead of print.ABSTRACTPatients with bone metastatic castration-resistant prostate cancer (mCRPC) might benefit from radium-223 (223Ra) combined with new-generation hormonal agents (NHAs) in terms of survival and quality of life (QoL). However, the safety of combination therapies remains unclear. Therefore, we aimed to perform a network meta-analysis by reviewing the literature about the combination of 223Ra with abiraterone acetate plus prednisone (AAP) or enzalutamide and to evaluate the safety of combination therapy in bone mCRPC patients. Ultimately, ten stud...
Source: Asian Journal of Andrology - January 25, 2023 Category: Urology & Nephrology Authors: Ming-Hao Wang Jin-Dong Dai Xing-Ming Zhang Jin-Ge Zhao Guang-Xi Sun Yu-Hao Zeng Hong Zeng Nan-Wei Xu Hao Zeng Peng-Fei Shen Source Type: research
The safety of radium-223 combined with new-generation hormonal agents in bone metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Asian J Androl. 2023 Jan 20. doi: 10.4103/aja2022108. Online ahead of print.ABSTRACTPatients with bone metastatic castration-resistant prostate cancer (mCRPC) might benefit from radium-223 (223Ra) combined with new-generation hormonal agents (NHAs) in terms of survival and quality of life (QoL). However, the safety of combination therapies remains unclear. Therefore, we aimed to perform a network meta-analysis by reviewing the literature about the combination of 223Ra with abiraterone acetate plus prednisone (AAP) or enzalutamide and to evaluate the safety of combination therapy in bone mCRPC patients. Ultimately, ten stud...
Source: Asian Journal of Andrology - January 25, 2023 Category: Urology & Nephrology Authors: Ming-Hao Wang Jin-Dong Dai Xing-Ming Zhang Jin-Ge Zhao Guang-Xi Sun Yu-Hao Zeng Hong Zeng Nan-Wei Xu Hao Zeng Peng-Fei Shen Source Type: research
The safety of radium-223 combined with new-generation hormonal agents in bone metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Asian J Androl. 2023 Jan 20. doi: 10.4103/aja2022108. Online ahead of print.ABSTRACTPatients with bone metastatic castration-resistant prostate cancer (mCRPC) might benefit from radium-223 (223Ra) combined with new-generation hormonal agents (NHAs) in terms of survival and quality of life (QoL). However, the safety of combination therapies remains unclear. Therefore, we aimed to perform a network meta-analysis by reviewing the literature about the combination of 223Ra with abiraterone acetate plus prednisone (AAP) or enzalutamide and to evaluate the safety of combination therapy in bone mCRPC patients. Ultimately, ten stud...
Source: Asian Journal of Andrology - January 25, 2023 Category: Urology & Nephrology Authors: Ming-Hao Wang Jin-Dong Dai Xing-Ming Zhang Jin-Ge Zhao Guang-Xi Sun Yu-Hao Zeng Hong Zeng Nan-Wei Xu Hao Zeng Peng-Fei Shen Source Type: research
The safety of radium-223 combined with new-generation hormonal agents in bone metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Asian J Androl. 2023 Jan 20. doi: 10.4103/aja2022108. Online ahead of print.ABSTRACTPatients with bone metastatic castration-resistant prostate cancer (mCRPC) might benefit from radium-223 (223Ra) combined with new-generation hormonal agents (NHAs) in terms of survival and quality of life (QoL). However, the safety of combination therapies remains unclear. Therefore, we aimed to perform a network meta-analysis by reviewing the literature about the combination of 223Ra with abiraterone acetate plus prednisone (AAP) or enzalutamide and to evaluate the safety of combination therapy in bone mCRPC patients. Ultimately, ten stud...
Source: Asian Journal of Andrology - January 25, 2023 Category: Urology & Nephrology Authors: Ming-Hao Wang Jin-Dong Dai Xing-Ming Zhang Jin-Ge Zhao Guang-Xi Sun Yu-Hao Zeng Hong Zeng Nan-Wei Xu Hao Zeng Peng-Fei Shen Source Type: research
Strong instrumental variables biased propensity scores in comparative effectiveness research: a case study in oncology
CONCLUSION: In setting of highly predictive pre-treatment procedures, excluding the immediate pre-exposure time from the CAP will reduce the risk of including potential IVs in PS models and may reduce bias.PMID:36657590 | DOI:10.1016/j.jclinepi.2023.01.002 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 19, 2023 Category: Cancer & Oncology Authors: Nicolas H Thurin J érémy Jové R égis Lassalle Magali Rouyer St éphanie Lamarque Pauline Bosco-Levy Corentin Segalas Sebastian Schneeweiss Patrick Blin C écile Droz-Perroteau Source Type: research
Novel hormonal therapies in the management of advanced prostate cancer: extrapolating Asian findings to Southeast Asia
There is a paucity of information on the use of novel hormonal agents in Southeast Asian patients. We reviewed the clinical roles of novel hormonal therapy (NHT), namely abiraterone acetate (AA), enzalutamide,... (Source: BMC Urology)
Source: BMC Urology - January 6, 2023 Category: Urology & Nephrology Authors: Teng Aik Ong, Marniza Saad, Jasmine Lim and Hsien Hooi Lee Tags: Research Source Type: research
A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer
CONCLUSION: The combination of capivasertib and abiraterone acetate had an acceptable tolerability profile consistent with the known profile of each agent. These data support further evaluation of capivasertib and abiraterone acetate in patients with advanced prostate cancer.PMID:36572571 | DOI:10.1016/j.clgc.2022.11.017 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - December 26, 2022 Category: Cancer & Oncology Authors: Neal Shore Bego ña Mellado Satish Shah Ralph Hauke Dan Costin Nabil Adra Marie Cullberg Carlos Fernandez Teruel Thomas Morris Source Type: research
A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer
CONCLUSION: The combination of capivasertib and abiraterone acetate had an acceptable tolerability profile consistent with the known profile of each agent. These data support further evaluation of capivasertib and abiraterone acetate in patients with advanced prostate cancer.PMID:36572571 | DOI:10.1016/j.clgc.2022.11.017 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - December 26, 2022 Category: Cancer & Oncology Authors: Neal Shore Bego ña Mellado Satish Shah Ralph Hauke Dan Costin Nabil Adra Marie Cullberg Carlos Fernandez Teruel Thomas Morris Source Type: research
